Recently, several small-molecule inhibitors selectively targeting IRAK4 have been shown to effectively abrogate aberrant NF-κB activation induced by MyD88L265P in ABC DLBCL, thus representing an attractive therapeutic strategy for the treatment of MyD88 mutant lymphoid malignancies [40,50]. This evidence concerns the gene IRAK4 and aneurysmal bone cyst.